Table 2.

PFS and OS by median of circulating VEGF-A for patients in the control group of the AVF2107, E4599, AVAiL, and AVOREN trials

PFSOS
StudynMedian, moHR (95% CI)PMedian, moHRP
AVF2107 (mCRC)
 Lowest 50%1016.93Reference0.148117.97Reference
 Highest 50%905.521.28 (0.92–1.80)12.881.76 (1.28–2.41)0.0005
E4599 (NSCLC)
 Lowest 50%375.59Reference0.490410.48Reference
 Highest 50%423.911.19 (0.72–1.96)8.541.31 (0.83–2.09)0.2510
AVAiL (NSCLC)
 Lowest 50%1436.44Reference0.196415.80Reference
 Highest 50%1535.951.17 (0.92–1.47)10.551.52 (1.16–2.00)0.0026
AVOREN (RCC)
 Lowest 50%957.43Reference0.268428.42Reference
 Highest 50%953.811.20 (0.87–1.65)15.281.67 (1.18–2.36)0.0035